NOU 2014: 12

Åpent og rettferdig – prioriteringer i helsetjenesten

Til innholdsfortegnelse


Adang E, Voordijk L, van der Wilt GJ, Ament A (2005). Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions. Health Policy 74: 146–56.

Adler MD (2011). Well-being and fair distribution: Beyond cost-benefit analysis. New York: Oxford University Press.

Alexander L (1992). What makes wrongful discrimination wrong? Biases, preferences, stereotypes, and proxies. University of Pennsylvania Law Review 141: 149–219.

Anand S (2002). The concern for equity in health. Journal of Epidemiology and Community Health 56: 485–7.

Andersen L, Schnohr P, Schroll M, Hein H (2000). All-cause mortality associated with physical activity during leisure time, work, sports, and cycling to work. Archives of Internal Medicine 160: 1621–8.

Andersson F og Lyttkens CH (1999). Preferences for equity in health behind a veil of ignorance. Health Economics 8: 369–78.

Anell A, Glenngård A, Merkur S (2012). Sweden: Health system review. Health Systems in Transition 14: 1–159.

Angell M (1993). The doctor as double agent. Kennedy Institute of Ethics Journal 3: 279–86.

Appleby J, Devlin N, Parkin D, Buxton M, Chalkidou K (2009). Searching for cost effectiveness thresholds in the NHS. Health Policy 91: 239–45.

Arbeids- og velferdsdirektoratet (2007). Betalingsordninger fysioterapi – forslag til alternative skjermingsordninger (rapport fra arbeidsgruppe). Oslo: Arbeids- og velferdsdirektoratet.

Arnarson EO og Craighead WE (2011). Prevention of depression among Icelandic adolescents: A 12-month follow-up. Behaviour Research and Therapy 49: 170–4.

Aronson JK, Ferner RE, Hughes DA (2012). Defining rewardable innovation in drug therapy. Nature Review Drug Discovery 11: 253–4.

Asada Y (2007). Health inequality: Morality and measurement. Toronto: University of Toronto Press.

Augustsson H og Hagquist WE (2011). Kartläggning av studier om nordiska ungdomars psykiska hälsa Göteborg: Nordiska högskolan för hälsovetenskap.

Baeten SA, Baltussen R, Uyl-de Groot CA, Bridges J, Niessen LW (2009). Incorporating equity–efficiency interactions in cost-effectiveness analysis–three approaches applied to breast cancer control. Value in Health 13: 573–9.

Barland J (2014). Proffere PR presser pressen. Gjøvik: Høgskolen i Gjøvik.

Basu A og Meltzer D (2005). Implications of spillover effects within the family for medical cost-effectiveness analysis. Journal of Health Economics 24: 751–73.

Bernd E (2002). Pharmaceuticals in US health care: Determinants of quantity and price. Journal of Economic Perspectives 16: 45–66.

Berwick D og Hackbarth A (2012). Eliminating waste in US health care. Journal of the American Medical Association 307: 1513–16.

Birch S og Gafni A (2006). Information created to evade reality (ICER). PharmacoEconomics 24: 1121–31.

Blair S et al. (1995). Changes in physical fitness and all-cause mortality: A prospective study of healthy and unhealthy men. Journal of the American Medical Association 273: 1093–8.

Bleichrodt H, Doctor J, Stolk E (2005). A nonparametric elicitation of the equity-efficiency trade-off in cost-utility analysis. Journal of Health Economics 24: 655–78.

Bobinac A, van Exel J, Rutten FFH, Brouwer WBF (2014). The value of a QALY: Individual willingness to pay for health gains under risk. PharmacoEconomics 32: 75–86.

Bobinac A, van Exel NJA, Rutten FFH, Brouwer WBF (2010). Willingness to pay for a quality-adjusted life-year: The individual perspective. Value in Health 13: 1046–55.

Bordvik M og Nilsen L (2014). Ungdom må vente i fire år på operasjon. Dagens Medisin. Oslo. [03.11.2014].

Botten G og Aasland O (2000). Befolkningens ønske om helsetjenester. Tidsskrift for Den norske legeforening 120: 2995–9.

Boumendil A et al. (2012). Variability of intensive care admission decisions for the very elderly. PLoS ONE 7: e34387.

Boyle S (2011). United kingdom (England): Health system review. Health Systems in Transition 13: 1–486.

Brazier J, Ratcliffe J, Salomon JA, Tsuchiya A (2007). Measuring and valuing health benefits for economic evaluation. Oxford: Oxford University Press.

Bridges JFP, Onukwugha E, Mullins DC (2010). Healthcare rationing by proxy: Cost-effectiveness analysis and the misuse of the $50 000 threshold in the US. PharmacoEconomics 28: 175–84.

Bringedal B og Bærøe K (2010). Bør leger bidra til å utjevne sosial ulikhet i helse? Tidsskrift for Den norske Legeforening 130: 1024–7.

Brock DW (2002a). Priority to the worse off in health-care resource prioritization, i Rhodes R, Battin MP og Silvers A (red.). Medicine and social justice: Essays on the distribution of health care. New York: Oxford University Press.

Brock DW (2002b). Fairness and health, i Murray CJ, Salomon JA, Mathers CD og Lopez AD (red.). Summary measures of population health: Concepts, ethics, measurement and applications. Geneva: World Health Organization.

Brock DW (2003). Separate spheres and indirect benefits. Cost Effectiveness and Resource Allocation 1.

Brock DW (2004). Ethical issues in the use of cost effectiveness analysis for the prioritization of health resources, i Khushf G (red.). Handbook of bioethics philosophy and medicine Rotterdam: Springer.

Brock DW (2009). Cost-effectiveness and disability discrimination. Economics and Philosophy 25.

Brock DW og Wikler D (2006). Ethical issues in resource allocation, research, and new product development, i Jamison DT et al. (red.). Disease control priorities in developing countries, 2 utg. New York: Oxford University Press.

Broqvist M, Elgstrand M, Carlsson P, Eklund K, Jakobsson A (2011). Nationell modell för öppna prioriteringar inom hälso- och sjukvård. Universitetet i Linköping. Linköping.

Brouwer WBF, Culyer AJ, van Exel NJA, Rutten FFH (2008). Welfarism vs. Extra-welfarism. Journal of Health Economics 27: 325–38.

Buchanan JM (2008). Opportunity cost, i Durlauf SN og Blume LE (red.). The new palgrave dictionary of economics, 2 utg. New York: Palgrave Macmillan.

Burston A og Tuckett A (2013). Moral distress in nursing: Contributing factors, outcomes and interventions. Nursing Ethics 20: 312–24.

Busse R og Blümel M (2014). Germany: Health system review. Health Systems in Transition 16: 1–296.

Buyx AM, Friedrich DR, Schöne-Seifert B (2011). Rationing by clinical effectiveness. British Medical Journal 342: d54.

Bærøe K (2009). Priority-setting in healthcare: A framework for reasonable clinical judgements. Journal of Medical Ethics 35: 488–96.

Calabresi G og Bobbitt P (1978). Tragic choices. New York: Norton.

Carlsen B og Norheim O (2005). Saying no is no easy matter: A qualitative study of competing concerns in rationing decisions in general practice. BMC Health Services Research 5: 70.

Carlsen B og Nyborg C (2009). The gate is open: Primary care physicians as social security gatekeepers. Department of Economics, University of Oslo.

Caro J et al. (2010). The efficiency frontier approach to economic evaluation of health-care interventions. Health Economics 19: 1117–27.

Chinitz D og Israeli A (1997). Health reform and rationing in Israel. Health Affairs 16: 205–10.

Chinitz D, Shalev C, Galai N, Israeli A (1998). The second phase of priority setting: Israel’s basic basket of health services: The importance of being explicitly implicit. British Medical Journal 317: 1005–7.

Claxton K (2007). OFT, VBP: QED? Health Economics 16: 545–58.

Claxton K et al. (2008). Value based princing for NHS drugs: An opportunity not to be missed. British Medical Journal 336: 251–4.

Claxton K, Longo R, Longworth L, McCabe C, Wailoo A (2009). The value of innovation. Report by the Decision Support Unit. [26.10.14].

Claxton K et al. (2013). Methods for the estimation of the NICE cost effectiveness threshold. Final report. CHE Research Paper. Centre for Health Economics, University of York.

Claxton K, Walker S, Palmer S, Schulper M (2010). Appropriate perspectives for health care decisions. CHE Research Paper 54. York: Centre for Health Economics, University of York.

Comanor W (1986). The political economy of the pharmaceutical industry. Journal of economic literature XXIV 1178–217.

Cookson R (2003). Willingness to pay methods in health care: A sceptical view. Health Economics 12: 891–4.

Cookson R (2013). Can the NICE «end-of-life premium» be given a coherent ethical justification? Health Economics, Policy and Law 38: 1129–4.

Cookson R og Dolan P (1999). Public views on health care rationing: A group discussion study. Health Policy 49: 63–74.

Cookson R og Dolan P (2000). Principles of justice in health care rationing. Journal of Medical Ethics 26: 323–9.

Council of the European Union (2009). Council recommendation. [26.10.14].

Cubbon J (1991). The principle of QALY maximisation as the basis for allocating health care resources. Journal of Medical Ethics 17: 181–4.

Cuijpers P, Muñoz RF, Clarke GN, Lewinsohn PM (2009). Psychoeducational treatment and prevention of depression: The «coping with depression» course thirty years later. Clinical Psychology Review 29: 449–58.

Culyer AJ og Wagstaff A (1993). Equity and equality in health and health care. Journal of Health Economics 12: 431–57.

Cutler D og Dafny L (2011). Designing transparency systems for medical care prices. New England Journal of Medicine 364: 894–5.

Daniels N (1994). Four unsolved rationing problems: A challenge. Hastings Center Report 24: 27–9.

Daniels N (2008). Just health: Meeting health needs fairly. Cambridge: Cambridge University Press.

Daniels N (2012). Reasonable disagreement about identifed vs statistical victims. Hastings Center Report 42: 35–45.

Daniels N og Sabin JE (2008). Setting limits fairly: Learning to share resources for health, 2. utg. Oxford: Oxford University Press.

De Hartog JJ, Boogaard H, Nijland H, Hoek G (2010). Do the health benefits of cycling outweigh the risks? Environmental Health Perspectives 118: 1109–16.

Deaton A (2012). What does the empirical evidence tell us about the injustice of health inequalities?, i Eyal N, Hurst S, Norheim OF og Wikler D (red.). Inequalities in health: Ethics and measurement. New York: Oxford University Press.

Defechereux T et al. (2012). Health care priority setting in Norway: A multicriteria decision analysis. BMC Health Services Research 12: 39.

Den norske legeforening (2014). Etiske regler for leger(nettside). [24.10.14].

Department of Health (2004). At least five a week. Evidence on the impact of physical activity and its relationship to health. A report from the Chief Medical Officer. London: Department of Health.

Desser AS, Gyrd-Hansen D, Olsen JA, Grepperud S, Kristiansen IS (2010). Societal views on orphan drugs: Cross sectional survey of Norwegians aged 40 to 67. British Medical Journal 341: c4715.

Direktoratet for forvaltning og IKT (2012). Graves det dypt nok? Om utredningsarbeid i departementene. Difi. Oslo.

Direktoratet for økonomistyring (2014). Veileder i samfunnsøkonomisk analyse. DFØ. Oslo.

Diserud G, Loeb M, Ekeberg O (2000). Suicidal behavior in the municipality of Baerum, Norway: A 12-year prospective study of parasuicide and suicide. Suicide and Life Threatening Behavior 30: 61–73.

DOH (2013). The UK strategy for rare diseases. Department of Health. [26.10.14].

Dolan P (1998). The measurement of individual utility and social welfare. Journal of Health Economics 17: 39–52.

Dolan P og Kahneman D (2008). Interpretations of utility and their implications for the valuation of health. The Economic Journal 118: 215–34.

Dolan P og Olsen JA (2002). Distributing health care: Economic and ethical issues. Oxford: Oxford University Press.

Dolan P, Shaw R, Tsuchiya A, Williams A (2005). QALY maximisation and people’s preferences: A methodological review of the literature. Health Economics 14: 197–208.

Dolan P og Tsuchiya A (2012). It is the lifetime that matters: Public preferences over maximising health and reducing inequalities in health. Journal of Medical Ethics 38: 571–3.

Donaldson C et al. (2010). European value of a quality adjusted life year. Final report. [27.10.14].

Drummond MF, Sculpher MJ, Torrance GW, O’Brien BJ, Stoddart GL (2005). Methods for the economic evaluation of health care programmes, 3 utg. New York: Oxford University Press.

Dworkin R (1983). Comment on Narveson: In defense of equality. Social Philosophy and Policy 1: 24–40.

Dworkin R (2000). Sovereign virtue: The theory and practice of equality. Cambridge, MA: Harvard University Press.

Eckermann S og Pekarsky B (2014). Can the real opportunity cost stand up: Displaced services, the straw man outside the room. PharmacoEconomis 32: 319–25.

Edgar W (2000). Rationing health care in New Zealand – how the public has a say, i Ham C og Coulter A (red.). The global challenges of health care rationing. Philadelphia: Open University Press.

Edlin R et al. (2008). Cost-effectiveness analysis and ageism: A review of the theoretical literature. Leeds Institute of Health Sciences, University of Leeds.

Eeg Skudal K, Bjærtnæs Ø, Holmboe O, Bukholm G, Røttingen J (2010). Commonwealth fund-undersøkelsen 2010: Resultater fra en komparativ befolkningsundersøkelse i 11 land. Oslo: Nasjonalt kunnskapssenter for helsetjenesten.

Eichler H-G, Sheldon KX, Gerth WC, Mavros P, Jönsson B (2004). Use of cost-effectiveness analysis in health-care resource allocation decision-making: How are cost-effectiveness thresholds expected to emerge? Value in Health 7: 518–28.

Eide A (2006). Retten til helse som menneskerettighet. Nordisk tidsskrift for menneskerettigheter 24: 274–90.

Eide M og Hernes G (1987). Død og pine! Om massemedia og helsepolitikk. Oslo: FAFO.

Elster J (1992). Local justice: How institutions allocate scarce goods and necessary burdens. New York: Russell Sage.

Elster J (red.) (1998). Deliberative democracy. Cambridge: Cambridge University Press.

Embriaco N et al. (2007). High level of burnout in intensivists. American Journal of Respiratory and Critical Care Medicine 175: 686–92.

Eriksen E og Weigård J (1999). Kommunikativ handling og deliberativt demokrati. Jürgen habermas’ teori om politikk og samfunn. Bergen: Fabokforlaget.

Eriksen I, Melberg H, Bringedal B (2013). Norwegian physicians’ knowledge of the prices of pharmaceuticals: A survey. PLoS ONE 8: e75218.

Eurordis (2014). What is a rare disease? (nettside). [20.10.14].

Faust HS og Menzel PT (red.) (2012). Prevention vs. Treatment: What’s the right balance? New York: Oxford University Press.

FDA (2009). Developing orphan products: FDA and rare disease day. Food and Drug Administration (FDA). Developing orphan products: FDA and rare disease day [26.10.14].

Feek C et al. (1999). Experience with rationing health care in New Zealand. British Medical Journal 318: 1346–8.

Feiring E (2004). Rettferdig rasjonering av sykehusbehandling (avhandling for graden dr. Polit). Institutt for statsvitenskap. Universitetet i Oslo. Oslo.

Feiring E (2006). Demokratiet og rettsliggjøringen av velferdspolitikken. Tidsskrift for samfunnsforskning 47: 575–87.

Ferner RE, Hughes DA, Aronson JK (2010). NICE and new: Appraising innovation. BMJ 340: b5493.

Finansdepartementet (2005). Veileder i samfunnsøkonomiske analyser. Oslo: Finansdepartementet.

Finansdepartementet (2013). Svar på spm. nr. 196 fra finanskomiteen/venstres fraksjon av 16. Oktober 2013. Oslo: Finansdepartementet.

Finansdepartementet (2014a). Rundskriv R-109/14 prinsipper og krav ved utarbeidelse av samfunnsøkonomiske analyser mv. Oslo: Finansdepartementet.

Finansdepartementet (2014b). Prop. 1 S Tillegg 1 (2014–15) Oslo: Finansdepartementet.

Fleck LM (2001). Last chance therapies: Can a just and caring society do health care rationing when life itself is at stake? Yale Journal of Health Policy, Law, and Ethics 2: 255–98.

FNs høykommissær for menneskerettigheter (2000). U.N. Committee on economic. Social and cultural rights. General comment 14: The right to the highest attainable standard of health. United Nations. Geneve.

Førde R og Pedersen R (2011). Clinical ethics committees in Norway: What do they do, and does it make a difference? Cambridge Quarterly of Healthcare Ethics 20: 389–95.

Førde R og Ruud Hansen T (2014). Do organizational and clinical ethics in a hospital setting need different venues? HEC Forum 26: 147–58.

Garvik M, Idsoe T, Bru E (2014). Effectiveness study of a cbt-based adolescent coping with depression course. Emotional and Behavioural Difficulties 19: 195–209.

Gericke CA, Riesberg A, Busse R (2005). Ethical issues in funding orphan drug research and development. Journal of Medical Ethics 31: 164–8.

Gillespie LD et al. (2012). Interventions for preventing falls in older people living in the community. Cochrane Database of Systematic Reviews 9: Cd007146.

Godager G, Hagen T, Iversen T (2014). Effekter av egenbetaling som virkemiddel for prioritering. Oslo: Helseøkonomisk Analyse AS.

Godager G, Iversen T, Lurås H (2012). Framtidens betalingssystemer i allmennlegetjenesten, i Melberg H og Kjekshus L (red.). Fremtidens helse-Norge. Bergen: Fagbokforlaget.

Gold M, Siegel J, Russell L, Weinstein M (1996). Cost-effectiveness in health and medicine. New York: Oxford University Press.

Green C og Gerrard K (2009). Exploring the social value of health care interventions: A stated preference discrete choice experiment. Health Economics 18: 951–76.

Griffin J (1986). Well-being: Its meaning, measurement and moral importance. Oxford: Clarendon Press.

Griffin SC, Claxton KP, Palmer SJ, Schulper MJ (2011). Dangerous omissions: The consequences of ignoring decision uncertainty. Health Economics 20: 212–24.

Gruskin S og Daniels N (2008). Process is the point: Justice and human rights: Priority setting and fair deliberative process. American Journal of Public Health 98: 1573–7.

Gutmann A og Thompson D (2004). Why deliberative democracy? Princeton, NJ: Princeton University Press.

Gyrd-Hansen D, Jensen ML, Kjaer T (2014). Framing the willingness-to-pay question: Impact on response patterns and mean willingness to pay. Health Economics 23: 550–63.

Habermas J (1996). Between facts and norms. New Baskerville: Massachusetts Institute of Technology.

Hadorn DC (1991). Setting health care priorities in oregon: Cost-effectiveness meets the rule of rescue. Journal of the American Medical Association 256: 2218–25.

Halvorsen K, Førde R, Nortvedt P (2009). The principle of justice in patient priorities in the intensive care unit: The role of significant others. Journal of Medical Ethics 35: 483–7.

Halvorsen M (2013). «Rett til nødvendig helsehjelp»: Endelig stemmer lovtekst og innhold overens! Lov og rett 52: 500–2.

Hatland A (2011). Rettsliggjøring av velferdspolitikken, i Hatland A (red.). Veivalg i velferdspolitikken. Bergen: Fagbokforlaget.

Hausman DM (2012). Measuring or valuing population health: Some conceptual problems. Public Health Ethics 5: 229–39.

Heiberg A, Frich J, Røttingen J-A (2014a). Sjeldenhet – eget kriterium ved prioritering? Tidsskrift for Den norske legeforening 134: 534–6.

Heiberg A, Frich J, Røttingen J-A (2014b). A. Heiberg og medarbeidere svarer. Tidsskrift for Den norske legeforening 134: 809–10.

Hektoen LF (2007). Fallforebyggende tiltak: En økonomisk vurdering. Masteroppgave. Oslo: Universitetet i Oslo.

Hektoen LF (2014). Kostnader ved hoftebrudd blant eldre. Høgskolen i Oslo og Akershus. Oslo.

Helbostad JL, Sletvold O, Moe-Nilssen R (2004). Effects of home exercises and group training on functional abilities in home-dwelling older persons with mobility and balance problems. A randomized study. Aging Clinical and Experimental Research 16: 113–21.

Hellman D. When is discrimination wrong? . Cambridge, MA: Harvard University Press.

Helse- og omsorgsdepartementet (2013). Høringsnotat: Endringer i blåreseptforskriften – nytt system for stønad til legemidler etter individuell søknad. Oslo: Helse- og omsorgsdepartementet.

Helse- og omsorgsdepartementet (2014a). HelseOmsorg21: Et kunnskapssystem for bedre folkehelse. Nasjonal forsknings- og innovasjonsstrategi for helse og omsorg. Oslo: Helse- og omsorgsdepartementet.

Helse- og omsorgsdepartementet (2014b). Høringsnotat datert 16. juni 2014 om fritt behandlingsvalg Oslo: Helse- og omsorgsdepartementet

Helse Sør-Øst RHF (2013). Medisinsk koding – tiltak som kan sikre at medisinsk koding utføres av godt kvalifiserte kodere. Hamar: Helse Sør-Øst RHF.

Helsebiblioteket (2014). Prioriteringsveiledere(nettside). retningslinjer/prioriteringsveiledere [24.10.14].

Helsedirektoratet (2007). Innsatsstyrt finansiering i helsetjenesten. En vurdering og aktuelle tiltak. Helsedirektoratet. Oslo

Helsedirektoratet (2008). Veileder for poliklinikker i psykisk helsevern for barn og unge. Oslo: Helsedirektoratet.

Helsedirektoratet (2009). Nasjonale retningslinjer for individuell primærforebygging av hjerte- og karsykdommer Oslo: Helsedirektoratet. nasjonal-faglig-retningslinje-for-individuell- primerforebygging-av-hjerte-og- karsykdommer/Publikasjoner/IS-1550.pdf. [24.10.14].

Helsedirektoratet (2010). Folkehelsearbeidet – veien til god helse for alle. Oslo: Helsedirektoratet.

Helsedirektoratet (2011a). Nasjonale faglige retningslinjer for diagnostikk, attakk- og sykdomsmodifiserende behandling av multippel sklerose. Oslo: Helsedirektoratet.

Helsedirektoratet (2011b). Høringsutgave: Samfunnsøkonomiske analyser i helsesektoren – en veileder. Oslo: Helsedirektoratet.

Helsedirektoratet (2012a). Prioriteringer i helsesektoren: Verdigrunnlag, status og utfordringer. Oslo: Helsedirektoratet.

Helsedirektoratet (2012b). Økonomisk evaluering av helsetiltak – en veileder. Oslo: Helsedirektoratet.

Helsedirektoratet (2013a). Overdiagnostikk og overbehandling. Oslo: Helsedirektoratet.

Helsedirektoratet (2013b). Nasjonalt system for innføring av nye metoder i spesialisthelsetjenesten. Systembeskrivelse. omsorgstjenester/system-for-innforing-av-nye- metoder-ny/Documents/ Systembeskrivelse.pdf [26.10.14].

Helsedirektoratet (2013c). Beslutningsprosesser ved begrensning av livsforlengende behandling. Oslo: Helsedirektoratet.

Helsedirektoratet (2013d). Fallforebygging i kommunen. Kunnskap og anbefalinger. Oslo: Helsedirektoratet.

Helsedirektoratet (2014a). Nasjonal overdosestrategi 2014–2017. Oslo: Helsedirektoratet.

Helsedirektoratet (2014b). Ventetider og pasientrettigheter 2013. Oslo: Helsedirektoratet.

Helsedirektoratet (2014c). Sjeldne diagnoser(nettside). helse-og-omsorgstjenester/sjeldne-tilstander/ Sider/default.aspx [26.10.14].

Helsedirektoratet (2014d). Innføring av nye metoder basert på en misforstått økonomisk «terskelverdi» kan gi samfunnsøkonomisk tap. Oslo: Helsedirektoratet.

Helsedirektoratet (2014e). Status og oversikt over metoder(nettside). omsorgstjenester/system-for-innforing-av-nye- metoder/innkomne-forslag/Sider/ default.aspx [28.10.14].

Henriksen I (1996). The effect of commuter cycling on physical performance and on coronary heart disease risk factors. Amsterdam: Free University.

Holm S (2000). Developments in the Nordic countries – goodbye to the simple solutions, i Ham C og Coulter A (red.). The global challenge of health care rationing. London: Open University Press.

Holmås TH og Kjerstad E (2010). Evaluering av tilskuddsordning for helse- og rehabiliteringstjenester. SNF-rapport nr. 07/10. Bergen: Samfunns- og næringslivsforskning AS.

Hughes DA, Tunnage B, Yeo ST (2005). Drugs for exceptionally rare diseases: Do they deserve special status for funding? QJM 98: 829–36.

Hurst SA (2009). Just care: Should doctors give priority to patients of low socioeconomic status? Journal of Medical Ethics 35: 7–11.

Hurst SA et al. (2007). Physicians’ views on resource availability and equity in four european health care systems. BMC Health Services Research 7: 137.

Høstmælingen N (2012). Internasjonale menneskerettigheter, 2 utg. Oslo: Universitetsforlaget.

Institute of Medicine (2010). Rare diseases and orphan products: Accelerating research and development. Washington DC: National Academies Press.

Ivarsflaten E og Roaldset J (2014). Holdninger til prioriteringer i helsesektoren: Resultater fra norsk medborgerpanel. Bergen: Universitetet i Bergen.

Jamison DT et al. (2013). Global health 2035: A world converging within a generation. Lancet 382: 1898–955.

Jensen SU (2006). Effekter av cykelstier og cykelbaner. Før- og efterevaluering af trafiksikkerhed og trafikmængder ved anleg af ensrettede cykelstier og cykelbaner i Københavns kommune. Lyngby: Trafitec.

Jia H, Zack MM, Thompson WW (2013). The effects of diabetes, hypertension, asthma, heart disease, and stroke on quality-adjusted life expectancy. Value in Health 16: 140–7.

Johannesson M og Johansson P-O (1997). Is the valuation of a QALY gained independent of age? Some empirical evidence. Journal of Health Economics 16: 589–99.

Johri M og Norheim OF (2012). Can cost-effectiveness analysis integrate concerns for equity? Systematic review. International Journal of Technology Assessment in Health Care 28: 125–32.

Jönsson B (2009). Ten arguments for a societal perspective in the economic evaluation of medical innovations. The European Journal of Health Economics 10: 357–9.

Kaczynski AT og Henderson KA (2014). Environmental correlates of physical activity: A review of evidence about parks and recreation. Leisure Science 29: 315–54.

Kamm FM (1993). Morality, mortality. Vol. 1: Death and whom to save from it. Oxford: Oxford University Press.

Kamm FM (1994). To whom? Hastings Center Report 24: 29–32.

Kapiriri L og Norheim OF (2004). Criteria for priority-setting in health care in uganda: Exploration of stakeholders’ values. Bulletin of the World Health Organization 82: 172–9.

Kappel K og Sandøe P (1994). Saving the young before the old – a reply to John Harris. Bioethics 8: 84–92.

Kelsey JL, Procter-Gray E, Hannan MT, Li W (2012). Heterogeneity of falls among older adults: Implications for public health prevention. Am J Public Health 102: 2149–56.

Kennedy I (2009). Appraising the value of innovation and other benefits: A short study for NICE. f/f8/KennedyStudyFinalReport.pdf [29.10.2014].

Kilner JF (1990). Who lives? Who dies? Ethical criteria in patient selection. New Haven: Yale University Press.

Kjønstad A (2007). Helserett, 2 utg. Oslo: Gyldendal forlag.

Kjønstad A og Syse A (2012). Velferdsrett I, 5 utg. Oslo: Gyldendal forlag.

Klein R, Day P, Redmayne S (1996). Managing scarcity: Priority setting and rationing in the national health service. Buckingham: Open University Press.

Kommunal- og moderniseringsdepartementet (2005). Instruks om utredning av konsekvenser, foreleggelse og høring ved arbeidet med offentlige utredninger, forskrifter, proposisjoner og meldinger til stortinget. Oslo: Kommunal- og moderniseringsdepartementet

Kravitz RL, Duan N, Braslow J (2004). Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Quarterly 82: 661–87.

Kristiansen IS og Gyrd-Hansen D (2007). Prioritering og helse – bør det innføres makspris på leveår? Tidsskrift for Den norske legeforening 127: 54–7.

Kristoffersen JA (2013). Utfordringer i fastlegeordningen, i Veggeland N (red.). Reformer i norsk helsevesen. Oslo: Akademika forlag

Kunnskapssenteret (2011). Slik oppsummerer vi forskning. Håndbok for Nasjonalt kunnskapssenter for helsetjenesten. 3. reviderte utg. Oslo: Nasjonalt kunnskapssenter for helsetjenesten.

Kvinnsland S (kommer). Pengar er ikkje alt. Helse i Vest.

Kymlicka W (2002). Contemporary political philosophy: An introduction, 2nd utg. Oxford: Oxford University Press.

Largent EA og Pearson SD (2012). Which orphans will find a home? The rule of rescue in resource allocation for rare diseases. Hastings Center Repport 42: 27–34.

Le Grand J (1989). An international comparison of distributions of ages-at-death, i Fox J (red.). Health inequalities in european countries. Gower: Aldershot.

Lim SS et al. (2012). A comparative risk assessment of burden of disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012 380.

Lind R, Lorem GF, Nortvedt P, Hevroy O (2011). Family members’ experiences of «wait and see» as a communication strategy in end-of-life decisions. Intensive Care Medicine 37: 1143–50.

Lindemark F, Norheim OF, Johansson KA (2014). Making use of equity sensitive QALYs: A case study on identifying the worse off across diseases. Cost Effectiveness and Resource Allocation 12: 16.

Lippert-Rasmussen K (2014). Born free and equal? A philosophical inquiry into the nature of discrimination. New York: Oxford University Press.

Lippert-Rasmussen K og Lauridsen S (2010). Justice and the allocation of healthcare resources: Should indirect, non-health effects count? Medicine, Health Care and Philosophy 13: 237–46.

Lord SR, Sherrington C, Menz HB, Close JCT (2007). Falls in older people: Risk factors and strategies for prevention, 2. utg. Cambridge University Press.

Lund J. and the European Network for Safety among Elderly (EUNESE) working group (2006). Priorities for elderly safety in europe – agenda for action. Athens University.

Mackenbach JP, Lingsma HF, van Ravesteyn NT, Kamphuis CBM (2012). The population and high-risk approaches to prevention: Quantitative estimates of their contribution to population health in the Netherlands. European Journal of Public Health 23: 909–15.

Major EF et al. (2011). Bedre føre var … psykisk helse: Helsefremmende og forebyggende tiltak og anbefalinger. Oslo: Nasjonalt folkehelseinstitutt.

Marmot M (2012). Fair society healthy lives, i Eyal N, Hurst S, Norheim OF og Wikler D (red.). Inequalities in health: Ethics and measurement. New York: Oxford University Press.

Marmot M et al. (2010). Fair society, healthy lives: The Marmot review. Ministry of Health UK. London.

Marmot M, Friel S, Bell R, Houweling TA, Taylor S (2008). Closing the gap in a generation: Health equity through action on the social determinants of health. Lancet 372: 1661–9.

Marsh K, Lanitis T, Neasham D, Orfanos P, Caro J (2014). Assessing the value of healthcare interventions using multi-criteria decision analysis: A review of the literature. PharmacoEconomics 32: 345–65.

Mazzucato M, Pozza LVD, Manea S, Minichiello C, Facchin P (2014). A population-based registry as a source of health indicators for rare diseases: The ten-year experience of the Veneto region’s rare diseases registry. Orphanet Journal of Rare Diseases 9: 37.

McAlister FA, Straus SE, Guyatt GH, Haynes RB (2000). Users’ guides to the medical literature: Integrating research evidence with the care of the individual patient. Journal of the American Medical Association 283: 2829–36.

McCabe C, Claxton K, Tsuchiya A (2005). Orphan drugs and the NHS: Should we value rarity? British Medical Journal, 331: 1016–9.

McCabe C, Tsuchiya A, Claxton K, Raftery J (2006). Orphan drugs revisited. QJM 99: 341–5; discussion 50–1.

McClure R et al. (2005). Population-based interventions for the prevention of fall-related injuries in older people. Cochrane Database Syst Rev: Cd004441.

McPherson K, Wennberg J, Hovind O, Clifford P (1982). Small-area variations in the use of common surgical procedures: An international comparison of new England, England, and Norway. New England Journal of Medicine 18: 1310–4.

Mehlum L, Jørgensen T, Diep LM, Nrugham L (2010). Is organizational change associated with increased rates of readmission to general hospital in suicide attempters? A 10-year prospective catchment area study. Archives of Suicide Research 14: 171–81.

Melberg HO (2012). Bruker Norge mye eller lite til helseformål sammenlignet med andre land? Oslo: Stortingets utredningsseksjon.

Melberg HO og Bringedal B (2010). Hva tror legene en MR-undersøkelse koster. Tidsskrift for Den norske legeforening 130: 598–600.

Meld. St. Nr. 5 (2003–2004) inntektssystem for spesialisthelsetjenesten (2003). Oslo: Helse- og omsorgsdepartementet.

Meld. St. Nr. 9 (2012–2013) Én innbygger – én journal. Digitale tjenester i helse- og omsorgssektoren (2012). Oslo: Helse- og omsorgsdepartementet.

Meld. St. Nr. 10. (2012–2013). God kvalitet – trygge tjenester. Kvalitet og pasientsikkerhet i helse- og omsorgstjenesten (2013). Oslo: Helse- og omsorgsdepartementet.

Menzel PT (2011). The value of life at the end of life: A critical assessment of hope and other factors. Journal of Law, Medicine & Ethics 39: 215–23.

Merry SN et al. (2012). Psychological and educational interventions for preventing depression in children and adolescents (review). Evidence-Based Child Health 7: I409-I685.

Mielke J, Douglas MK, Singer PA (2003). Priority setting in a hospital critical care unit: Qualitative case study. Critical Care Medicine 31: 2764–8.

Moe I og Hultgren J (2009). De yngste får vaksine først. Aftenposten, 2.11.09.

Molven O (2012). Sykepleie og jus, 4 utg. Oslo: Gyldendal norsk forlag.

Moynihan R, Doust J, Henry D (2012). Preventing overdiagnosis: How to stop harming the healthy. British Medical Journal 344: e3502.

Muñoz RF, Schueller SM, Barrera AZ, Le H-N, Torres LD (2014). Major depression can be prevented. Implications for research and practice, i Gotlib IH og Hammen CL (red.). Handbook of depression, 3. utg. New York: Guilford Press.

Murhpy D (2009). Concepts of disease and health. The Stanford Encyclopedia of Philosophy [early view]. Available: archives/sum2009/entries/health-disease/.

Murray CJL og et al (2012b). Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990–2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380: 2197–223.

Murray CJL et al. (2012a). GBD 2010: Design, definitions, and metrics. Lancet 380: 2063–6.

Murray CJL og Mokdad A (2013). Integrated surveillance systems: Getting the most out of the health information system. The Health Information Systems Knowledge Hub’s Working Paper Series. Brisbane: University of Queensland.

Musgrove P (1999). Public spending on health care: How are different criteria related? Health Policy 47: 207–23.

Mørland B, Ringard Å, Røttingen J (2010). Supporting tough decisions in Norway: A healthcare system approach. International Journal of Technology Assessment in Health Care 26: 398–404.

Nagel T (1991). Equality and partiality. New York: Oxford University Press.

Narum I og Bergland A (2010). Forskningsbasert fallforebyggende arbeid i kommunehelsetjenesten: En litteraturstudie. Høgskolen i Oslo.

Narum I og Bergland A (2011). Forskningsbasert fallforebyggende arbeid i kommunehelsetjenesten: Utprøving av forskningsbasert kunnskap. Høgskolen i Oslo. Oslo.

Nasjonalt kunnskapssenter for helsetjenesten (2011). Slik oppsummerer vi forskning. Håndbok for nasjonalt kunnskapssenter for helsetjenesten. Nasjonalt kunnskapssenter for helsetjenesten. Oslo. vi-tilby/sjekklister-for-vurdering-av- forskningsartikler/_attachment/ 13438?_ts=133a2c26dc4.

Nasjonalt råd (2010). Hvordan sikre et godt og likeverdig behandlingstilbud for sjeldne tilstander? hvordan-sikre-et-godt-og-likeverdig- behandlingstilbud-for-sjeldne-tilstander [26.10.14].

Nasjonalt råd (2012). Grenseverdi for offentlig betalingsvilje for effekt av tiltak i helsetjenesten. Saksframlegg. Saksnummer 2012/140. _attachment/14739?_download= true&_ts=13af3cc376f [28.10.14].

National Institute of Mental Health (2014). Major depression among adolescents. prevalence/major-depression-among- adolescents.shtml [28.10.14].

Neuberger J, Adams D, MacMaster P, Maidment A, Speed M (1998). Assessing priorities for allocation of donor liver grafts: Survey of public and clinicians. British Medical Journal 317: 172–5.

Neuman P og Weinstein M (2010). Legislating against use of cost-effectiveness information. New England Journal of Medicine 363: 1495–7.

NICE (2008a). Physical activity and the environment. London: National Institute for Health and Care Excellence.

NICE (2008b). Guidance on the promotion and creation of physical environments that support increased levels of physical activity. London: National Institute for Health and Care Excellence.

NICE (2013). Guide to the methods of technology appraisal 2013. National Institute for Health and Care Excellence. [24.10.14].

NICE (2014a). Value based assessment of health technologies. Consultation paper. National Institute for Health and Care Excellence.

NICE (2014b). Illustrative technology appraisal list and QALY shortfall. National Institute for Health and Care Excellence. About/what-we-do/NICE-guidance/ NICE-technology-appraisals/Illustrative- TA-list-and-QALY-shortfall.pdf [27.10.14].

Noorani HZ, Husereau DR, Boudreau R, Skidmore B (2007). Priority setting for health technology assessments: A systematic review of current practical approaches. Internatonal Journal of Technology Assessment in Health Care 23: 310–5.

Nord E (1993). The trade-off between severity of illness and treatment effect in cost-value analysis of health care. Health Policy 24: 227–38.

Nord E (1999). Cost-value analysis in health care: Making sense out of QALYs. New York: Cambridge University Press.

Nord E (2005). Concerns for the worse off: Fair innings versus severity. Social Science & Medicine 60: 257–63.

Nord E (2014). Sjeldenhet – eget kriterium ved prioritering? Tidsskrift for Den norske legeforening 134: 809.

Nord E, Daniels N, Kamlet M (2009). QALYs: Some challenges. Value in Health 12: S10–5.

Nord E og Johansen R (2014). Concerns for severity in priority setting in health care: A review of trade-off data in preference studies and implications for societal willingness to pay for a QALY. Health Policy 116: 281–8.

Nord E, Pinto JL, Richardson J, Menzel P, Ubel P (1999). Incorporating societal concerns for fairness in numerical valuations of health programmes. Health Economics 8: 25–39.

Nord E, Richardson J, Street A, Kuhse H, Singer P (1995). Who cares about cost? Does economic analysis impose or reflect social values? Health Policy 34: 79–94.

Nord E, Street A, Richardson J, Kuhse H, Singer P (1996). The significance of age and duration of effect in social evaluation of health care. Health Care Analysis 4: 103–11.

Norderhaug I, Fure B, Reinar L, Klemp M, Jamtvedt G (2012). Hva er en metodevurdering (HTA), en systematisk oversikt og en metaanalyse – når og hvordan brukes de? Michael Quartely 9: 109–17.

Norgeshelsa (2014). Norhealth(nettside). [28.10.14].

Norheim O et al. (2011). Norway’s new principles for primary prevention of cardiovascular disease: Age differentiated risk thresholds British Medical Journal 343: 3626.

Norheim OF. 1996. Limiting access to health care: A contractualist approach to fair rationing. PhD, Universitetet i Oslo.

Norheim OF (1999). Healthcare rationing–are additional criteria needed for assessing evidence based clinical practice guidelines? British Medical Journal 319: 1426–9.

Norheim OF (2008). Clinical priority setting. British Medical Journal 337: a1846.

Norheim OF (2009). A note on Brock: Prioritarianism, egalitarianism and the distribution of life years. Journal of Medical Ethics 35: 565–9.

Norheim OF og Asada Y (2009). The ideal of equal health revisited: Definitions and measures of inequity in health should be better integrated with theories of distributive justice. International Journal for Equity in Health 8: 40.

Norheim OF et al. (2014). Guidance on priority setting in health care (GPS health): The inclusion of equity criteria not captured by cost-effectiveness analysis. Cost Effectiveness and Resource Allocation 12: 18.

Norsk intensivregister (2013). Årsrapport for 2012. LinkClick.aspx?fileticket= C6y7hQoWLK0%3d&tabid=55&mid= 377&forcedownload=true [26.10.14].

NOU (1987: 23). Retningslinjer for prioritering innen norsk helsetjeneste. Oslo: Universitetsforlaget.

NOU (1991: 10). Flere gode leveår for alle. Forebyggingsstrategier Sosialdepartementet. Oslo: Statens forvaltningstjeneste.

NOU (1997: 7). Piller, prioritering og politikk. Hva slags refusjonsordning trenger pasienter og samfunn? Oslo: Statens forvaltningstjeneste.

NOU (1997: 18). Prioritering på ny: Gjennomgang av retningslinjer for prioriteringer innen norsk helsetjeneste. Oslo: Statens forvaltningstjeneste.

NOU (1997: 20). Omsorg og kunnskap! Norsk kreftplan. Sosial- og helsedepartementet. Oslo: Statens forvaltningstjeneste.

NOU (2007:4). Ny uførestønad og ny alderspensjon til uføre. Arbeids- og inkluderingsdepartementet. Oslo: Departementenes servicesenter.

NOU (2011: 11). Innovasjon i omsorg. Helse- og omsorgsdepartementet. Oslo: Departementenes servicesenter.

NOU (2012:16). Samfunnsøkonomiske analyser. Oslo: Departementenes servicesenter.

Nærings- og fiskeridepartementet (2008). St.Meld. Nr. 7 (2007–2008) et nyskapende og bærekraftig Norge. Oslo: Nærings- og fiskeridepartementet.

OECD (2014). Reviews of health care quality: Norway. Paris: OECD

Oja P et al. (1991). Physiological effects of walking and cycling to work. Scandinavian Journal of Medicine, Science and Sports 1: 151–7.

Oja P, Vuori I, Paronen O (1998). Daily walking and cycling to work: Their utility as health-enhancing physical activity. Patient Education and Counseling 33: S87-S94.

Olejaz M et al. (2012). Denmark: Health system review. Health Systems in Transition 14: 1–192.

Olsen JA (2013a). Priority preferences: «End of life» does not matter, but total life does. Value in Health 16.

Olsen JA (2013b). Hva menes med «sykdommens alvorlighetsgrad». Tidsskrift for Den norske legeforening 133: 64–7.

Olsen JA, Donaldson C, Pereira J (2004). The insensitivity of ‘willingness-to-pay’ to the size of the good: New evidence for health care. Journal of Economic Psychology 25: 445–60.

Olsen JA og Richardson J (1999). Production gains from health care: What should be included in cost-eectiveness analyses? Social Science & Medicine 49: 17–26.

Omachonu VK og Einspruch NG (2010). Innovation in healthcare delivery systems: A conceptual framework. Innovation Journal 15.

Omsland TK et al. (2014). Mortality following the first hip fracture in norwegian women and men (1999–2008). A norepos study. Bone 63c: 81–6.

Omsland TK et al. (2012). Hip fractures in Norway 1999–2008: Time trends in total incidence and second hip fracture rates: A norepos study. European Journal of Epidemiology 27: 807–14.

Omsland TK og Magnus JH (2014). Forecasting the burden of future postmenopausal hip fractures. Osteoporos Int 25: 2493–6.

Ord T (2013). The moral imperative toward cost-effectiveness in global health. Center for Global Development Essay. Washington DC: Center for Global Development.

Orr S, Wolff J, Morris S (2011). What values should count in HTA for new medicines under value based princing in the UK? [29.10.2014].

Ot. Prp. Nr. 10 (1998–99) om lov om spesialisthelsetjenesten m.m. (1998). Oslo: Helse- og omsorgsdepartementet.

Ottersen T (2013). Lifetime QALY prioritarianism in priority setting. Journal of Medical Ethics 39: 175–80.

Ottersen T, Mæstad O, Norheim OF (2014). Lifetime QALY prioritarianism in priority setting: Empirical quantification of the inherent trade-off. Cost Effectiveness and Resource Allocation 12.

Parfit D (1995). Equality or priority? Kansas: University of Kansas.

Pedersen R og Førde R (2005). Hva gjør de kliniske etikkomiteene? Tidsskrift for Den norske legeforening 125: 3127–9.

Pekarsky BAK (2012). Trust, constraints and the counterfactual: Reframing the political economy of new drugs. PhD thesis. University of Adelaide. bitstream/2440/79171/3/02whole.pdf [26.10.14].

Persad G, Wertheimer A, Emanuel EJ (2009). Principles for allocation of scarce medical interventions. Lancet 373: 423–31.

Pettersen R (2002). Falltendens hos gamle Tidsskrift for Den norske legeforening 122: 631–4.

Pinxten W, Denier Y, Dooms M, Cassiman JJ, Dierickx K (2012). A fair share for the orphans: Ethical guidelines for a fair distribution of resources within the bounds of the 10-year-old european orphan drug regulation. Journal of Medical Ethics 38: 148–53.

Polisena J et al. (2013). Case studies that illustrate disinvestment and resource allocation decision-making processes in health care: A systematic review. International Journal of Technology Assessment in Health Care 29: 174–84.

Pornak S, Meyer T, Raspe H (2011). The danish debate on priority setting in medicine – characteristics and results. Gesundheitswesen 73: 680–7.

Prop. 91 L (2010–2011) lov om kommunale helse- og omsorgstjenester m.m. (helse- og omsorgstjenesteloven) (2011). Oslo: Helse- og omsorgsdepartementet.

Prop. 118 L (2012–2013) endringer i pasient- og brukerrettighetsloven mv. (rett til nødvendig helsehjelp og pasientrettighetsdirektivet m.m.) (2013). Oslo: Helse- og omsorgsdepartementet.

Raftery JP (2014). NICE’s cost-effectiveness range: Should it be lowered? PharmacoEconomics 32: 613–5.

Rawlins MD (2005). Pharmacopolitics and deliberative democracy. Clinical Medicine 5: 471–5.

Rawlins MD og Culyer AJ (2004). National institute for clinical excellence and its value judgements. British Medical Journal 329: 224–6.

Rawls J (1993). Political liberalism. New York: Columbia University Press.

Rawls J (1999). A theory of justice, Revidert utg. Cambridge, MA: Harvard University Press.

REK (2014). En nasjonal fase IV studie med legemiddelet ipilimumab for pasienter med langtkommet føflekkreft(nettside). ikbViewer/page/prosjekterirek/ prosjektregister/prosjekt?p_document_id= 402871&p_parent_id=407281&_ ikbLanguageCode=n [25.05.14].

Rice T et al. (2013). United States of America: Health system review. Health Systems in Transition 15: 1–431.

Richardson J, McKie J, Bariola E (2014). ‘Multiattribute utility instruments and their use’. Amsterdam: Elsevier.

Richardson JRJ, McKie J, Peacock SJ, Iezzi A (2011). Severity as an independent determinant of the social value of a health service. European Journal of Health Economics 12: 163–74.

Ridley D (2005). Price differentiation and transparency in the global pharmaceutical marketplace. Pharmacoeconomics 23: 651–8.

Riksrevisjonen (2013). Riksrevisjonens undersøkelse av om offentlige tiltak utredes på en tilfredsstillende måte Riksrevisjonen. Oslo.

Ringard Å, Mørland B, Larsen B (2012). Kvalitet og prioritering i helsetjenesten. Tidsskrift for Den norske legeforening: 312–4.

Ringard Å, Mørland B, Røttingen J (2010). Åpne prosesser for prioritering. Tidsskrift for Den norske legeforening: 2264–6.

Ringard Å, Saunes I, Sagan A, Lindahl A (2013). Norway: Health system review. Health Systems in Transition 15: 1–162.

Rose G (1992). Strategy of preventive medicine. Oxford: Oxford University Press.

Ryen L og Svensson M (2014). The willingness to pay for a quality adjusted life year: A review of the empirical literature. Health Economics [early view].

Ryynänen O-P, Myllykangas M, Kinnunen J, Takala J (1999). Attitudes to health care prioritisation methods and criteria among nurses, doctors, politicians and the general public. Social Science & Medicine 49: 1529–39.

Sabik LM og Lie RK (2008). Priority setting in health care: Lessons from the experiences of eight countries. International Journal for Equity in Health 7: 4.

Saelens BE, Sallis JF, Frank LD (2003). Environmental correlates of walking and cycling: Findings from the transportation, urban design, and planning literatures. Annals of Behavioral Medicine 25: 80–91.

Salman RA et al. (2014). Increasing value and reducing waste in biomedical research regulation and management. Lancet 383: 176–85.

Salomon JA et al. (2012). Healthy life expectancy for 187 countries, 1990–2010: A systematic analysis for the global burden disease study 2010. Lancet 380: 2144–62.

Santesso N, Carrasco-Labra A, Brignardello-Petersen R (2014). Hip protectors for preventing hip fractures in older people. Cochrane Database Syst Rev 3: Cd001255.

Saunes I og Ringard Å (2013). Hva gjøres for å bedre pasientsikkerheten? Satsinger i sju land. Nasjonalt kunnskapssenter for helsetjenesten. Oslo.

Scheunemann LP og White DB (2011). The ethics and reality of rationing in medicine. Chest 140: 1625–32.

Schiøtz A (2003). Det offentlige helsevesen i Norge – folkets helse – landets styrke 1850–2003. Oslo: Universitetsforlaget.

Schwappach DLB (2002). Resource allocation, social values and the QALY: A review of the debate and empirical evidence. Health Expectations 5: 210–22.

Schäfer W et al. (2010). The Netherlands: Health system review. Health Systems in Transition 12: 1–229.

Segall S (2007). Is health care (still) special? Journal of Political Philosophy 15: 342–61.

Segall S (2010). Health, luck, and justice. New Jersey: Princeton University Press.

Sen AK (1980). Equality of what?, i McMurrin S (red.). Tanner lectures on human values. Cambridge: Cambridge University Press.

Sen AK (1987). The standard of living: Lecture i, concepts and critiques, i Hawthorn G (red.). The standard of living. Cambridge Cambridge University Press.

Sen AK (1992). Inequality reexamined. Cambridge, MA: Harvard University Press.

Sen AK (1993). Capability and well-being, i Nussbaum M og Sen A (red.). The quality of life. Oxford: Claredon Press.

Sen AK (2002). Why health equity? Health Economics 11: 659–66.

Senter for medisinsk etikk (2013). Årsrapport 2013 kliniske etikk-komiteer. Universitetet i Oslo.

Shah KK (2009). Severity of illness and priority setting in healthcare: A review of the literature. Health Policy 93: 77–84.

Shani S, Siebzehner M, Luxenberg O, Shemer J (2000). Setting priorities for the adoption of health technologies on a national level–the Israeli experience. Health Policy 54: 169–85.

Singer P, McKie J, Kuhse H, Richardson J (1995). Double jeopardy and the use of QALYs in health care allocation. Journal of Medical Ethics 21: 144–50.

Sinuff T, Kahnamoui K, Cook DJ, Luce JM, Levy MM (2004). Rationing critical care beds: A systematic review. Critical Care Medicine 32: 1588–97.

Skår Å et al. (2014). Livets sluttfase – om å finne passende behandlingsnivå og behandlingsintensitet for alvorlig syke og døende. Oslo: Nasjonalt kunnskapssenter for helsetjenesten.

Sosial- og helsedepartementet (1997). St. Meld. Nr. 23 (1996–1997) trygghet og ansvarlighet: Om legetjenesten i kommunene og fastlegeordningen. Oslo: Sosial- og helsedepartementet.

Sosial- og helsedepartementet (1999). St. Meld. Nr. 26 (1999–2000) om verdiar for den norske helsetenesta. Oslo: Sosial- og helsedepartementet.

Sosial- og helsedirektoratet (2005). Sosial- og helsedirektoratets handlingsplan mot sosiale ulikheter i helse. Gradientutfordringen. Sosial- og helsedirektoratet. Oslo.

SOU (1993). Vårdens svåra val. Rapport från utredningen om prioriteringear innom hälso- og sjukvården. Stockholm: Statens offentliga utredningar.

SOU (1995). Vårdens svåra val. 1995:5. Statens offentliga utredninger. Stockholm: Socialdepartementet.

Sprung CL et al. (2012). The Eldicus prospective, observational study of triage decision making in european intensive care units: Part I – European intensive care admission triage scores. Critical Care Medicine 40: 125–31.

Sprung CL et al. (2013). Triage of intensive care patients: Identifying agreement and controversy. Intensive Care Medicine 39: 1916–24.

Statens legemiddelverk (2012). Retningslinjer for legemiddeløkonomiske analyser. Statens legemiddelverk. Oslo.

Statens legemiddelverk (2014). Retningslinjer for prisfastsettelse. [26.10.14].

Stolk EA, van Donselaar G, Brouwer WB, Busschbach JJ (2004). Reconciliation of economic concerns and health policy: Illustration of an equity adjustment procedure using proportional shortfall. Pharmacoeconomics 22: 1097–107.

Strand K og Flaatten H (2008). Severity scoring in the ICU: A review. Acta Anaesthesiologica Scandinavica 52: 467–78.

Strech D, Synofzik M, Marckmann G (2008). How physicians allocate scarce resources at the bedside: A systematic review of qualitative studies. Journal of Medicine and Philosophy 33: 80–99.

Strosberg MA og Teres D (2003). Intensive care unit admissions do not pass the reasonableness test. Critical Care Medicine 31: 2809–11.

Sælensminde K (2002). Bygging av gang- og sykkelvegnett mer lønnsomt enn de fleste vegprosjekter. Samferdsel 3.

Sælensminde K (2002). Gang- og sykkelvegnett i norske byer. Nytte- kostnadsanalyser inkludert helseeffekter og eksterne kostnader av motorisert vegtrafikk. TØI rapport 567/2002. Oslo: Transportøkonomisk institutt.

Task Force of the American College of Critical Care Medicine (1999). Guidelines for intensive care unit admission, discharge, and triage. Critical Care Medicine 27: 633–8.

The Cochrane Collaboration (2011). ‘Cochrane handbook for systematic reviews of interventions version 5.1.0 (updated march 2011)’. The Cochrane Collaboration.

Tirole J (1988). The theory of industrial organization. Cambridge, MA: Massachusetts Institute of Technology.

Tjelta LI, Kvåle OH, Dyrstad SM (2010). Helseeffekter av sykling til og fra jobb. Tidsskrift for Den norske legeforening 130: 1246–9.

Tjerbo T og Hagen T (2013). Historien om da kostnadskontroll spiste new public management til middag, i Veggeland N (red.). Reformer i norsk helsevesen : Veier videre. Oslo: Akademika forlag.

Tretvik T (2008). Sykkelbyundersøkelse 2008 Region sør. Sintef rapport A7914. Trondheim: Sintef.

Tsuchiya A (2000). QALYs and ageism: Philosophical theories and age weighting. Health Economics 9: 57–68.

U.S. Department of Health and Human Services (1996). Physical activity and health: A report of the surgeon general. Atlanta: U.S. Department of Health and Human Services, Center for Disease Control and Prevention, National Center for Chronic Disease Prevention and Health Promotion.

Ubel PA (1999). How stable are people’s preferences for giving priority to severely ill patients? Social Science & Medicine 49: 895–903.

Ubel PA og Loewenstein G (1996). Distributing scarce livers: The moral reasoning of the general public. Social Science & Medicine 7: 1049–55.

Ubel PA, Spraca M, DeKay M, Hershey J (1998). Public preferences for prevention versus cure. Medical Decision Making 18: 141–8.

UNDP (2013). Human development report 2013: The rise of the south: Human progress in a diverse world. United Nations Development Programme. New York: United Nations Development Programme.

van de Wetering EJ, Stolk EA, van Exel NJ, Brouwer WB (2013). Balancing equity and efficiency in the dutch basic benefits package using the principle of proportional shortfall. The European journal of health economics 14: 107–15.

Varian H og Repcheck J (2010). Intermediate microeconomics: A modern approach. New York: WW Norton & Company.

Varkey P, Horne A, Bennet KE (2008). Innovation in health care: A primer. American Journal of Medical Quality 23: 382–8.

Vaupel J, Zhang Z, van Raalte A (2011). Life expectancy and disparity: An international comparison of life table data. BMJ Open: 1:e000128.

Vegdirektoratet (2012). Nasjonal sykkelstrategi – sats på sykkel! VD-rapport nr. 7. Oslo: Vegdirektoratet.

Vernon JA, Goldberg R, Golec J (2009). Economic evaluation and cost-effectiveness thresholds: Signals to firms and implications for r&d investment and innovation. PharmacoEconomics 27: 797–806.

Voorhoeve A (2014). How should we aggregate competing claims? Ethics 125: 64–87.

Vos T et al. (2012). Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: A systematic analysis for the Global Burden of Disease Study 2010. Lancet 380: 2163–96.

Vourenkoski L, Mladovsky P, Mossialos E (2008). Finland: Health system review. Health Systems in Transition 10: 1–168.

Vuori I, Oja P, Paronen O (1994). Physically active commuting to work – testing its potential for exercise promotion. Medicine and Science in Sports and Exercise 26: 844–50.

Walker S, Schulper M, Claxton K, Palmer S (2012). Coverage with evidence development, only in research, risk sharing, or patient access scheme? A framework for coverage decisions. Value in Health 15: 570–9.

Weare K og Nind M (2011). Mental health promotion and problem prevention in schools: What does the evidence say? Health Promotion International 26: i29-i69.

Webb DJ og Walker A (2007). Value-based pricing of drugs in the UK. Lancet 369: 1415–6.

Welch H, Schwartz L og Woloshin S (2011). Overdiagnosed : Making people sick in the pursuit of health. Boston: Beacon Press.

Wennberg J og Gittelsohn A (1973). Small area variations in health care delivery. Science 182: 1102–8.

Werntoft E og Edberg A-K (2009). The views of physicians and politicians concerning age-related prioritisation in healthcare. Journal of Health Organization and Management 23: 38–52.

WHO (1948). Preamble to the constitution of the world health organization as adopted by the international health conference. Official Records of the World Health Organization, no. 2.

WHO (2000). The world health report 2000. Health systems: Improving performance. Geneva: World Health Organization.

WHO (2007). Everybody’s business: Strengthening health systems to improve health outcomes: WHO’s framework for action. Geneva: World Health Organization.

WHO (2010). The world health report: Health systems financing: The path to universal coverage. Geneva: World Health Organization.

WHO (2014a). World health statistics 2014. Geneva: World Health Organization.

WHO (2014b). Making fair choices on the path to universal health coverage. Final report of the WHO Consultative Group on Equity and Universal Health Coverage. Geneva: World Health Organization.

Williams A (1992). Cost-effectiveness analysis: Is it ethical? Journal of Medical Ethics 18: 7–11.

Williams A (1997). Intergenerational equity: An exploration of the ‘fair innings’ argument. Health Economics 6: 117–32.

Winberg A, Broqvist M, Blomquist U-B (2014). Att prioritera på individnivå: Beslutsstöd vid hjälpmedelsförskrivning. Prioriteringscentrum. sjukvardsanalys/prioriteringscentrum/ publikationer/att-prioritera-pa-individniva/ 1.583692/Rapport-2014–2_B_web.pdf [27.10.14].

Wisløff T et al. (2014). Estimating QALY gains in applied studies: A review of cost-utility analyses published in 2010. PharmacoEconomics 32: 367–75.

Wittenberg E og Prosser LA (2013). Disutility of illness for caregivers and families: A systematic review of the literature. PharmacoEconomics 31: 489–500.

Wright A, Zhang B, Ray A (2008). Associations between end-of-life discussions, patient mental health, medical care near death, and caregiver bereavement adjustment. Journal of the American Medical Association 300: 1665–73.

Yang L, Sahlqvist S, McMinn A, Griffin SJ, Ogilvie D (2010). Interventions to promote cycling: Systematic review. British Medical Journal 341: c5293.

Zhang B, Wright A, Huskamp H (2009). Health care costs in the last week of life: Associations with end-of-life conversations. Archives of Internal Medicine 169: 480–8.

Liste over lover og forskrifter nevnt i NOU

Lov 28. Februar 1997 nr. 19 om folketrygd (folketrygdloven).

Lov 7. juni 1999 nr. 61 om spesialisthelsetjenesten m.m. (spesialisthelsetjenesteloven).

Lov 2. juli 1999 nr. 63 om pasient- og brukerrettigheter (pasientrettighetsloven).

Lov 2. juli 1999 nr. 64 om helsepersonell m.v. (helsepersonelloven).

Lov 24. juni 2011 nr. 30 om kommunale helse- og omsorgstjenester m.m. (helse- og omsorgstjenesteloven).

Forskrift 1. Desember 2000 nr. 1208 om prioritering av helsetjenester, rett til nødvendig helsehjelp fra spesialisthelsetjenesten, rett til behandling i utlandet og om klagenemnd (prioriteringsforskriften).

Forskrift 7. Desember 2007 nr. 1389 om innsamling og behandling av helseopplysninger i norsk pasientregister (norsk pasientregisterforskriften).

Forskrift 28. juni 2007 nr. 814 om stønad til dekning av utgifter til viktige legemidler mv. (blåreseptforskriften).

Forskrift 18. Desember 2009 nr. 1839 om legemidler (legemiddelforskriften).

Forskrift 29. August 2012 nr 842 om fastlegeordning i kommunene.

Forskrift 20. juni 2014 nr. 812 om stønad til dekning av utgifter til fysioterapi m.m.

Til forsiden